Patient-Derived Organoid (PDO) Development Services

In oncology drug discovery, preclinical models that accurately preserve patient-specific tumor architecture, mutational landscape, and drug response are critical for translational success. Traditional 2D cell lines lack tumor complexity, while patient-derived xenografts (PDXs) are costly and time-consuming. Alfa Cytology offers comprehensive patient-derived organoid (PDO) development services designed to establish, expand, and characterize 3D organoids directly from patient tumor tissues, delivering clinically relevant ex vivo models that accelerate drug screening, biomarker discovery, and personalized therapy assessment.

Introduction to Patient-Derived Organoid (PDO)

Patient-derived organoid (PDO) development represents a paradigm shift in preclinical oncology. PDOs are three-dimensional, self-organizing structures derived from disaggregated patient tumor specimens (surgical resections, core needle biopsies, or endoscopic samples). These models faithfully recapitulate the histological, genetic, and functional heterogeneity of original tumors—including cancer stem cell populations and stromal interactions, while maintaining genomic stability across passages. Unlike PDXs that require months to establish, PDOs can be generated within 2–4 weeks, enabling rapid functional testing. They are fully compatible with high-throughput drug screening, CRISPR-based gene editing, and co-culture systems, bridging the gap between patient genomics and therapeutic decision-making.

Fig. 1 Procedure for the generation of patient-derived organoid (PDO). (Thorel L, et al.; 2024)

Applications of CTC-Derived Organoid

Our Services

Alfa Cytology offers a comprehensive PDO development service that transforms routine tumor specimens into patient-relevant 3D models for drug screening, mechanism studies, and co-culture applications. By preserving the cellular heterogeneity and microenvironmental context of primary tumors, our platform generates organoids that retain authentic drug response profiles and genetic architecture.

Unlike conventional PDX models that require months of engraftment time, our efficient PDO workflow generates functional models within weeks, enabling rapid, serial assessment of drug sensitivity and resistance evolution. The resulting PDO biobank provides the biological relevance and scalability necessary for precision oncology and translational research.

Workflow of Patient-Derived Organoid (PDO) Development

Supported Cancer Types

Platforms & Facility

Alfa Cytology offers flexible patient-derived organoid development packages customized to your specific program needs, whether you require rapid PDO establishment for drug screening, full histologic and genomic characterization, immune co-culture modeling, or longitudinal resistance studies from serial patient biopsies. Our team of organoid biology and translational oncology specialists is ready to assist with tumor type feasibility assessment, media optimization, and data interpretation. If you seek further exploration of PDO development services for your precision oncology programs, please feel free to contact us.

For research use only.